News
Sino Biopharm Was Invited to Participate in the Development of the "ESG Management Code for the Pharmaceutical and Health Industry"
Release time：2022-10-20
On September 16, 2022, the "ESG Forum for Pharmaceutical and Health Industry and the Online Launch Meeting of the ESG Management Code for Pharmaceutical and Health Industry" hosted by the China Pharmaceutical Industry Association was successfully held. The conference brought together leading institutions and enterprises in China's economic, financial, pharmaceutical and health industries, including the Institute of Finance of the Development Research Center of the State Council and the Institute of World Economics and Politics of the Chinese Academy of Social Sciences, with the aim of exchanging in-depth experience in the development of ESG in China's pharmaceutical industry and jointly building ESG risk management and disclosure standards for the pharmaceutical and health industry with Chinese characteristics. -The ESG Management Code for the Pharmaceutical and Health Industry.
At the same time, Sino Biopharm, as one of the participants in the formulation of "ESG Management Code for Pharmaceutical and Health Industry", launched the formulation of "ESG Management Code for Pharmaceutical and Health Industry" together with China Pharmaceutical Industry Association at the conference. In the future, Sino Biopharm will continue to combine its own ESG work experience to provide professional opinions and suggestions for the "ESG Management Code for Pharmaceutical and Health Industry" and contribute to the promotion of high-quality and sustainable development of the pharmaceutical industry.
The invitation represents the wide recognition of the industry and society for the company's continuous deep commitment in the ESG field. As a leading innovative research and R&D-driven pharmaceutical group in China, the Group will always uphold the value of "for the country, the people and the enterprise", support the strategy of a healthy China, seek health and well-being for more patients, and allow more diseases to be treated, as well as continuously commit to promoting the harmonious development of the enterprise, employees, society and the environment, and create long-term value for itself and its partners. At the same time, we will continue to be committed to promoting the harmonious development of the enterprise, employees, society and the environment, creating long-term value for ourselves and our partners.